[go: up one dir, main page]

PE20181003A1 - Compuestos terapeuticos y sus metodos de uso - Google Patents

Compuestos terapeuticos y sus metodos de uso

Info

Publication number
PE20181003A1
PE20181003A1 PE2018000486A PE2018000486A PE20181003A1 PE 20181003 A1 PE20181003 A1 PE 20181003A1 PE 2018000486 A PE2018000486 A PE 2018000486A PE 2018000486 A PE2018000486 A PE 2018000486A PE 20181003 A1 PE20181003 A1 PE 20181003A1
Authority
PE
Peru
Prior art keywords
group
alkyl
membered
membered heterocyclyl
thiadiazol
Prior art date
Application number
PE2018000486A
Other languages
English (en)
Inventor
Phillipe Bergeron
Kristen Burford
Sultan Chowdhury
Christoph Martin Dehnhardt
Thilo Focken
Michael Edward Grimwood
Abid Hasan
Kwong Wah Lai
Zhiguo Liu
Steven Mckerrall
Teresa Phuongtram Nguyen
Brian Safina
Daniel Sutherlin
Tao Wang
Original Assignee
Genentech Inc
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Xenon Pharmaceuticals Inc filed Critical Genentech Inc
Publication of PE20181003A1 publication Critical patent/PE20181003A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invencion refiere a compuesto organicos de formulas (I), (Ix) y (II): donde: RAA se selecciona del grupo que consiste en F, Cl, Br, I, -CN, entre otros; el anillo A es un heteroarilo de 5-12 miembros o un heterociclilo de 3-15 miembros; el anillo B es un carbociclilo de 5,6 o 7 miembros o un heterociclilo de 5,6 o 7 miembros; R1a es H o alquilo C1-C4; R1b es H o alquilo C1-C4; R2 se selecciona del grupo que consiste en H, F, Cl, entre otros; R3, R4 y R5 se seleccionan cada uno independientemente del grupo que consiste en H, F, Br, -CN, entre otros; R6 se selecciona del grupo que consiste en H, alquilo C1-C8, cicloalquilo C3-C8, arilo, entre otros; R7 se selecciona del grupo que consiste en alquilo C1-C8, heterociclilo de 3-15 miembros, heteroarilo de 5-12 miembros, entre otros; R8 se selecciona del grupo que consiste en H, alquilo C1-C8, arilo, entre otros; R9 se selecciona del grupo que consiste en cicloalquilo C3-C8, alquiloC1-C8; H, entre otros. Son compuestos preferidos; (S)-4-((4,4-dimetil-2-fenilpiperidin-1-il)metil)-2,5-difluoro-N-(1,2,4-tiadiazol-5-il)bencenosulfonamida; 2,5-difluoro-4-(((2S,4R)-2-fenil-4-(trifluorometil)piperidin-1-il)metil)-N-(1,2,4-tiadiazol-5-il)bencenosulfonamida, entre otros. Tambien refiere una composicion farmaceutica que comprende compuestos organicos de formulas (I), (Ix) y (II) y un excipiente farmaceuticamente aceptable. La presente invencion es util para el tratamiento de depresion, enfermedades cardiovasculares, enfermedades respiratorias y enfermedades pisquiatricas.
PE2018000486A 2015-09-28 2016-09-27 Compuestos terapeuticos y sus metodos de uso PE20181003A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562233863P 2015-09-28 2015-09-28
US201662298817P 2016-02-23 2016-02-23
CN2016096659 2016-08-25

Publications (1)

Publication Number Publication Date
PE20181003A1 true PE20181003A1 (es) 2018-06-26

Family

ID=57137267

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000486A PE20181003A1 (es) 2015-09-28 2016-09-27 Compuestos terapeuticos y sus metodos de uso

Country Status (21)

Country Link
US (2) US10787446B2 (es)
EP (1) EP3356360A1 (es)
JP (1) JP6987746B2 (es)
KR (1) KR20180067561A (es)
CN (1) CN108290881B (es)
AU (1) AU2016330503B2 (es)
BR (1) BR112018006189A2 (es)
CA (1) CA2999769A1 (es)
CL (1) CL2018000805A1 (es)
CO (1) CO2018003909A2 (es)
CR (1) CR20180242A (es)
HK (1) HK1258056A1 (es)
IL (1) IL258192A (es)
MX (1) MX386501B (es)
PE (1) PE20181003A1 (es)
PH (1) PH12018500668A1 (es)
RU (1) RU2018115718A (es)
SG (1) SG10202007787RA (es)
TW (1) TWI726916B (es)
WO (1) WO2017058821A1 (es)
ZA (1) ZA201802134B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10793550B2 (en) 2017-03-24 2020-10-06 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
CN112321494B (zh) * 2020-11-17 2022-04-19 上海凌凯医药科技有限公司 一种制备2-氯-4-异丙基吡啶的方法
WO2023028056A1 (en) * 2021-08-24 2023-03-02 Genentech, Inc. 3-amino piperidyl sodium channel inhibitors
TWI860146B (zh) * 2023-10-30 2024-10-21 泰盈光電股份有限公司 電致變色組成物及電致變色裝置

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3705185A (en) 1969-04-14 1972-12-05 Minnesota Mining & Mfg N-aroyl sulfonamides
JPS59140445A (ja) * 1983-01-31 1984-08-11 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
GB8524157D0 (en) 1984-10-19 1985-11-06 Ici America Inc Heterocyclic amides
US5096771A (en) 1988-07-14 1992-03-17 General Electric Company Fibers impregnated with epoxy resin mixture, brominated bisphenol and polyphenylene ether
DK24089D0 (da) 1989-01-20 1989-01-20 Hans Bundgaard Novel prodrug derivatives of biologically active agents containing hydroxyl groups or nh-acidic groups
GB8904174D0 (en) * 1989-02-23 1989-04-05 British Bio Technology Compounds
GB8911854D0 (en) 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
IL101860A0 (en) 1991-05-31 1992-12-30 Ici Plc Heterocyclic derivatives
AU690529B2 (en) 1992-11-23 1998-04-30 Hoechst Marion Roussel, Inc. Substituted 3-(aminoalkylamino)-1,2-benzisoxazoles and related compounds
US5573653A (en) 1994-07-11 1996-11-12 Sandoz Ltd. Electrochemical process for thiocyanating aminobenzene compounds
GB9510477D0 (en) 1995-05-24 1995-07-19 Sandoz Ltd Organic compounds
US5753653A (en) 1995-12-08 1998-05-19 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
KR20000022380A (ko) * 1996-07-01 2000-04-25 둘락 노먼 씨. 무스카린 길항제
GB9828442D0 (en) 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
KR100789567B1 (ko) 2001-11-06 2007-12-28 동화약품공업주식회사 3-아미도-1,2-벤조이소옥사졸 유도체, 그 염, 제조방법 및 용도
DE10201550A1 (de) 2002-01-17 2003-07-31 Merck Patent Gmbh Phenoxy-Piperidine
DE60330150D1 (en) 2002-08-08 2009-12-31 Memory Pharmaceutical Corp Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
US7132425B2 (en) 2002-12-12 2006-11-07 Hoffmann-La Roche Inc. 5-substituted-six-membered heteroaromatic glucokinase activators
EP1615899A1 (en) 2003-04-15 2006-01-18 Pfizer Inc. Alpha-substituted carboxylic acids as ppar modulators
CN1863785A (zh) 2003-08-08 2006-11-15 沃泰克斯药物股份有限公司 在疼痛的治疗中用作钠或钙通道阻断剂的杂芳基氨基磺酰基苯基衍生物
JP2007501804A (ja) 2003-08-08 2007-02-01 バーテックス　ファーマシューティカルズ　インコーポレイテッド 電位開口型のナトリウムチャネルのインヒビターとして有用な組成物
JP2007507551A (ja) 2003-10-03 2007-03-29 ポートラ ファーマシューティカルズ， インコーポレイテッド ２，４−ジオキソ−３−キナゾリニルアリールスルホニル尿素
US7081539B2 (en) 2004-03-25 2006-07-25 Dainippon Sumitomo Pharma Co., Ltd. One-pot process for the preparation of 1,2-benzisoxazole-3-methanesulfonamide
JP2008508306A (ja) 2004-07-30 2008-03-21 メルク エンド カムパニー インコーポレーテッド メタボトロピックグルタミン酸受容体のインダノン増強剤
CA2576993C (en) 2004-08-12 2013-09-24 Amgen Inc. Bisaryl-sulfonamides
KR20070064356A (ko) 2004-09-29 2007-06-20 포톨라 파마슈티컬스, 인코포레이티드 치환된 2ｈ-1,3-벤족사진-4(3ｈ)온
CA2599419A1 (en) * 2005-04-22 2006-11-02 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-iv inhibitors
WO2006122014A2 (en) * 2005-05-10 2006-11-16 Vertex Pharmaceuticals Incorporated Bicyclic derivatives as modulators of ion channels
JP2008189549A (ja) 2005-05-12 2008-08-21 Astellas Pharma Inc カルボン酸誘導体またはその塩
DE102005038947A1 (de) 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
EP1922311A2 (en) 2005-09-09 2008-05-21 Brystol-Myers Squibb Company Acyclic ikur inhibitors
AU2006303367A1 (en) 2005-10-19 2007-04-26 F. Hoffmann-La Roche Ag N-phenyl phenylacetamide non-nucleoside reverse transcriptase inihibitors
BRPI0620532A2 (pt) 2005-11-23 2011-11-16 Ligand Pharm Inc compostos e métodos para modular a atividade de trombopoietina
AR058296A1 (es) 2005-12-09 2008-01-30 Kalypsys Inc Inhibidores de histona desacetilasa y composicion farmaceutica
KR20080109918A (ko) 2006-04-11 2008-12-17 버텍스 파마슈티칼스 인코포레이티드 전압 개폐 나트륨 채널의 억제제로서 유용한 조성물
US7700593B2 (en) 2006-10-11 2010-04-20 Amgen Inc. Imidazo- and triazolo-pyridine compounds and methods of use thereof
AU2008211108A1 (en) 2007-01-30 2008-08-07 Biogen Idec Ma Inc. 1-h-pyrazolo (3,4b) pyrimidine derivatives and their use as modulators of mitotic kinases
CA2677493A1 (en) 2007-02-05 2008-08-14 Xenon Pharmaceuticals Inc. Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions
US20080261978A1 (en) * 2007-03-08 2008-10-23 Clark Michael P Chemokine receptor modulators
ATE461177T1 (de) 2007-03-23 2010-04-15 Icagen Inc Ionenkanal-hemmer
CA2687764A1 (en) 2007-05-25 2008-12-04 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
MX2009013355A (es) 2007-06-07 2010-02-22 Astellas Pharma Inc Compuesto de piridona.
US20090012103A1 (en) 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
TW200911766A (en) 2007-07-13 2009-03-16 Astrazeneca Ab New compounds
EP2173743A2 (en) 2007-07-13 2010-04-14 Icagen, Inc. Sodium channel inhibitors
US20110092703A1 (en) 2007-08-10 2011-04-21 Nippon Chemiphar Co., Ltd. P2x4 receptor antagonist
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
US20110052562A1 (en) * 2007-12-19 2011-03-03 The Scripps Research Institute Benzimidazoles and analogs as rho kinase inhibitors
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
LT2262778T (lt) * 2008-03-07 2019-11-11 Acraf 1-benzil-3-hidroksimetilindazolo dariniai ir jų panaudojimas gydant ligas, pagrįstas mcp-1, cxcr1 ir p40 raiška
WO2009157399A1 (ja) 2008-06-23 2009-12-30 アステラス製薬株式会社 スルホンアミド化合物又はその塩
WO2010022055A2 (en) 2008-08-20 2010-02-25 Amgen Inc. Inhibitors of voltage-gated sodium channels
EP2385938B1 (en) 2009-01-12 2015-03-04 Pfizer Limited Sulfonamide derivatives
WO2010137351A1 (en) 2009-05-29 2010-12-02 Raqualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
RS56410B1 (sr) 2009-07-27 2018-01-31 Gilead Sciences Inc Fuzionisana heterociklična jedinjenja kao modulatori jonskih kanala
US8809380B2 (en) 2009-08-04 2014-08-19 Raqualia Pharma Inc. Picolinamide derivatives as TTX-S blockers
MX2012003560A (es) 2009-09-25 2012-10-05 Astellas Pharma Inc Compuesto de amida sustituida.
WO2011059042A1 (ja) 2009-11-12 2011-05-19 武田薬品工業株式会社 芳香環化合物
US8471034B2 (en) 2009-11-18 2013-06-25 Concert Pharmaceuticals, Inc. Niacin prodrugs and deuterated versions thereof
TW201139406A (en) 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
RS54618B1 (sr) 2010-02-12 2016-08-31 Nivalis Therapeutics, Inc. Novi inhibitori s-nitrozoglutation reduktaze
WO2011153588A1 (en) 2010-06-10 2011-12-15 Biota Scientific Management Pty Ltd Viral polymerase inhibitors
JP2013530013A (ja) 2010-06-30 2013-07-25 カーディアック ペースメイカーズ， インコーポレイテッド 優先的屈曲領域を有するコイル電極付リード
WO2012004664A2 (en) 2010-07-07 2012-01-12 Purdue Pharma L.P. Analogs of sodium channel peptide toxin
US9145407B2 (en) 2010-07-09 2015-09-29 Pfizer Limited Sulfonamide compounds
JP5830534B2 (ja) 2010-07-09 2015-12-09 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 化合物
CA2803118C (en) 2010-07-09 2015-11-03 Pfizer Limited Sulfonamide derivatives as nav 1.7 inhibitors
EP2593431B1 (en) 2010-07-12 2014-11-19 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
CA2804877A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
EP2593428B1 (en) 2010-07-12 2014-11-19 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
ES2526541T3 (es) 2010-07-12 2015-01-13 Pfizer Limited N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje
EP2593432B1 (en) 2010-07-12 2014-10-22 Pfizer Limited N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
EP2593434A1 (en) 2010-07-16 2013-05-22 Purdue Pharma LP Pyridine compounds as sodium channel blockers
JP2013537180A (ja) 2010-09-13 2013-09-30 ノバルティス アーゲー トリアジン−オキサジアゾール類
WO2012039657A1 (en) 2010-09-22 2012-03-29 Astrazeneca Ab Novel chromane compound for the treatment of pain disorders
WO2012085650A1 (en) 2010-12-22 2012-06-28 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
WO2012095781A1 (en) 2011-01-13 2012-07-19 Pfizer Limited Indazole derivatives as sodium channel inhibitors
AU2012212196B2 (en) 2011-02-02 2016-10-13 Vertex Pharmaceuticals Incorporated Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels
EP2744805A1 (en) 2011-08-17 2014-06-25 Amgen Inc. Heteroaryl sodium channel inhibitors
JP2014528486A (ja) 2011-10-13 2014-10-27 ケース ウエスタン リザーブ ユニバーシティ Ｒｘｒアゴニスト化合物および方法
KR20140095067A (ko) 2011-10-28 2014-07-31 머크 샤프 앤드 돔 코포레이션 전압-게이팅 나트륨 채널에서의 선택적 활성을 갖는 벤족사졸리논 화합물
CA2855019A1 (en) 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
MX2014005297A (es) 2011-10-31 2014-09-11 Xenon Pharmaceuticals Inc Compuestos de bencenosulfonamida y su uso como agentes terapeuticos.
WO2013072758A1 (en) 2011-11-15 2013-05-23 Purdue Pharma L.P. Pyrimidine diol amides as sodium channel blockers
WO2013086229A1 (en) * 2011-12-07 2013-06-13 Amgen Inc. Bicyclic aryl and heteroaryl sodium channel inhibitors
EP2791108B1 (en) 2011-12-15 2016-07-27 Pfizer Limited Sulfonamide derivatives
CA2860553C (en) 2012-01-04 2016-08-23 Pfizer Limited N-aminosulfonyl benzamides
JP2015083542A (ja) 2012-02-08 2015-04-30 大日本住友製薬株式会社 ３位置換プロリン誘導体
US8889741B2 (en) 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
WO2013122897A1 (en) 2012-02-13 2013-08-22 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
WO2013134518A1 (en) 2012-03-09 2013-09-12 Amgen Inc. Sulfamide sodium channel inhibitors
WO2013146969A1 (ja) 2012-03-29 2013-10-03 第一三共株式会社 新規二置換シクロヘキサン誘導体
EP2855428A1 (en) 2012-05-22 2015-04-08 Genentech, Inc. N-substituted benzamides and their use in the treatment of pain
CA2878478A1 (en) 2012-07-06 2014-01-09 Genentech, Inc. N-substituted benzamides and methods of use thereof
CN104640843A (zh) 2012-07-19 2015-05-20 大日本住友制药株式会社 1-(环烷基羰基)脯氨酸衍生物
RU2015119640A (ru) 2012-10-26 2016-12-20 Мерк Шарп И Доум Корп. Соединения n-замещенного индазол-сульфонамида с избирательной активностью в потенциал-зависимых натриевых каналах
RU2015119635A (ru) 2012-10-26 2016-12-20 Мерк Шарп И Доум Корп. Соединения бензоксазолинона с избирательной активностью в потенциал-зависимых натриевых каналах
US9714252B2 (en) 2012-12-20 2017-07-25 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
AP2015008633A0 (en) 2013-01-31 2015-07-31 Vertex Pharma Pyridone amides as modulators of sodium channels
US20140296266A1 (en) 2013-03-01 2014-10-02 Gilead Sciences, Inc. Therapeutic compounds
US9550775B2 (en) 2013-03-14 2017-01-24 Genentech, Inc. Substituted triazolopyridines and methods of use thereof
ES2687481T3 (es) 2013-03-15 2018-10-25 Chromocell Corporation Moduladores del canal de sodio para el tratamiento del dolor
CA2898680A1 (en) 2013-03-15 2014-09-18 Genentech,Inc. Substituted benzoxazoles and methods of use thereof
US9663508B2 (en) 2013-10-01 2017-05-30 Amgen Inc. Biaryl acyl-sulfonamide compounds as sodium channel inhibitors
KR20160090846A (ko) 2013-11-27 2016-08-01 제넨테크, 인크. 치환된 벤즈아마이드 및 이의 이용 방법
EP3297989A1 (en) 2015-05-22 2018-03-28 Genentech, Inc. Substituted benzamides and methods of use thereof
US10793550B2 (en) * 2017-03-24 2020-10-06 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors

Also Published As

Publication number Publication date
WO2017058821A1 (en) 2017-04-06
KR20180067561A (ko) 2018-06-20
CL2018000805A1 (es) 2018-07-06
MX2018003828A (es) 2018-06-22
TW201718556A (zh) 2017-06-01
US10787446B2 (en) 2020-09-29
PH12018500668A1 (en) 2018-10-01
US20210171516A1 (en) 2021-06-10
EP3356360A1 (en) 2018-08-08
TWI726916B (zh) 2021-05-11
IL258192A (en) 2018-05-31
US20180291014A1 (en) 2018-10-11
ZA201802134B (en) 2020-08-26
SG10202007787RA (en) 2020-09-29
BR112018006189A2 (pt) 2018-10-09
JP2018533551A (ja) 2018-11-15
AU2016330503A1 (en) 2018-04-12
RU2018115718A3 (es) 2019-12-27
CN108290881A (zh) 2018-07-17
AU2016330503B2 (en) 2021-04-08
CA2999769A1 (en) 2017-04-06
HK1258056A1 (zh) 2019-11-01
RU2018115718A (ru) 2019-10-28
JP6987746B2 (ja) 2022-01-05
AU2016330503A8 (en) 2018-04-19
CN108290881B (zh) 2021-12-07
MX386501B (es) 2025-03-19
CO2018003909A2 (es) 2018-07-19
CR20180242A (es) 2018-08-10

Similar Documents

Publication Publication Date Title
PE20250674A1 (es) Compuestos heterociclicos como inmunomoduladores
PE20141824A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
CY1123994T1 (el) Δικυκλικες-συντηγμενες ενωσεις ετεροαρυλιου ή αρυλιου ως ρυθμιστες της irak4
CY1123395T1 (el) Ενωσεις καρβοξαμιδιων ινδολης χρησιμες ως αναστολεις κινασων
CO2019007711A2 (es) N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga
PE20181003A1 (es) Compuestos terapeuticos y sus metodos de uso
MX2020003415A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
PE20170004A1 (es) Inhibidores de biaril cinasa
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
CO2018002060A2 (es) Compuestos farmacéuticos
ES2770058T3 (es) Compuestos y composiciones destinados a modular las actividades de quinasa de EGFR mutante
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
PE20161372A1 (es) Inhibidores de dihidropirrolopiridina de ror-gamma
PE20170268A1 (es) Compuestos de heteroarilo para la inhibicion de cinasa
PE20151542A1 (es) Compuestos de tetrahidropirrolotiazina
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
PE20130602A1 (es) Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a
PE20161225A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
PE20161443A1 (es) Compuestos
MX2018016419A (es) Derivados de n-(sustituida-fenil)-sulfonamida como inhibidores de quinasa n-(sustituida-fenil)-sulfonamida.
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos
PE20181074A1 (es) Compuestos heteroaromaticos como inhibidores de btk
PE20141352A1 (es) Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento
PE20240930A1 (es) Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton